B3. A study to determine the role of iNOS as a radiosensitizer and potentiator of bioreductive drugs in human tumours

Nitric Oxide ◽  
2007 ◽  
Vol 17 ◽  
pp. 16
Author(s):  
B. Fitzpatrick ◽  
M. Babur ◽  
B. Telfer ◽  
E. Chinje ◽  
R. Cowen ◽  
...  
2004 ◽  
Vol 91 (03) ◽  
pp. 438-449 ◽  
Author(s):  
Michelle Durand ◽  
Julie Bødker ◽  
Anni Christensen ◽  
Daniel Dupont ◽  
Martin Hansen ◽  
...  

SummaryIn recent decades, evidence has been accumulating showing the important role of urokinase-type plasminogen activator (uPA) in growth, invasion, and metastasis of malignant tumours. The evidence comes from results with animal tumour models and from the observation that a high level of uPA in human tumours is associated with a poor patient prognosis. It therefore initially came as a surprise that a high tumour level of the uPA inhibitor plasminogen activator inhibitor-1 (PAI-1) is also associated with a poor prognosis, the PAI-1 level in fact being one of the most informative biochemical prognostic markers. We review here recent investigations into the possible tumour biological role of PAI-1, performed by animal tumour models, histological examination of human tumours, and new knowledge about the molecular interactions of PAI-1 possibly underlying its tumour biological functions. The exact tumour biological functions of PAI-1 remain uncertain but PAI-1 seems to be multifunctional as PAI-1 is expressed by multiple cell types and has multiple molecular interactions. The potential utilisation of PAI-1 as a target for anti-cancer therapy depends on further mapping of these functions.


1981 ◽  
Vol 43 (5) ◽  
pp. 669-683 ◽  
Author(s):  
J E Byfield ◽  
J Murnane ◽  
J F Ward ◽  
P Calabro-Jones ◽  
M Lynch ◽  
...  

Author(s):  
T. M. Mukherjee ◽  
J. G. Swift

The freeze-fracture technique is unique in its ability to expose extensive face views of the interior of the cell membranes. This feature is particularly useful for studies of events occurring at the plasma membrane, such as exocytosis of secretory granules and of structural components within the membrane such as the intercellular junctions. We have used freeze-fracture preparations in conjunction with conventional thin sections to study the intercellular junctions in a variety of human tumours.


2017 ◽  
Author(s):  
Bernardo Rodriguez-Martin ◽  
Eva G. Alvarez ◽  
Adrian Baez-Ortega ◽  
Jorge Zamora ◽  
Fran Supek ◽  
...  

AbstractAbout half of all cancers have somatic integrations of retrotransposons. To characterize their role in oncogenesis, we analyzed the patterns and mechanisms of somatic retrotransposition in 2,954 cancer genomes from 37 histological cancer subtypes. We identified 19,166 somatically acquired retrotransposition events, affecting 35% of samples, and spanning a range of event types. L1 insertions emerged as the first most frequent type of somatic structural variation in esophageal adenocarcinoma, and the second most frequent in head-and-neck and colorectal cancers. Aberrant L1 integrations can delete megabase-scale regions of a chromosome, sometimes removing tumour suppressor genes, as well as inducing complex translocations and large-scale duplications. Somatic retrotranspositions can also initiate breakage-fusion-bridge cycles, leading to high-level amplification of oncogenes. These observations illuminate a relevant role of L1 retrotransposition in remodeling the cancer genome, with potential implications in the development of human tumours.


2020 ◽  
Vol 43 (6) ◽  
pp. 1003-1016
Author(s):  
Claudio D’Amore ◽  
Christian Borgo ◽  
Stefania Sarno ◽  
Mauro Salvi

Abstract Background Protein kinase CK2 inhibition has long been considered as an attractive anti-cancer strategy based on the following considerations: CK2 is a pro-survival kinase, it is frequently over-expressed in human tumours and its over-expression correlates with a worse prognosis. Preclinical evidence strongly supports the feasibility of this target and, although dozens of CK2 inhibitors have been described in the literature so far, CX-4945 (silmitasertib) was the first that entered into clinical trials for the treatment of both human haematological and solid tumours. However, kinase inhibitor monotherapies turned out to be effective only in a limited number of malignancies, probably due to the multifaceted causes that underlie them, supporting the emerging view that multi-targeted approaches to treat human tumours could be more effective. Conclusions In this review, we will address combined anti-cancer therapeutic strategies described so far which involve the use of CX-4945. Data from preclinical studies clearly show the ability of CX-4945 to synergistically cooperate with different classes of anti-neoplastic agents, thereby contributing to an orchestrated anti-tumour action against multiple targets. Overall, these promising outcomes support the translation of CX-4945 combined therapies into clinical anti-cancer applications.


Cytokine ◽  
2001 ◽  
Vol 15 (1) ◽  
pp. 27-38 ◽  
Author(s):  
Donatella R.M. Negri ◽  
Delia Mezzanzanica ◽  
Silvano Sacco ◽  
Massimo Gadina ◽  
Fabio Benigni ◽  
...  

JAMA ◽  
1966 ◽  
Vol 195 (12) ◽  
pp. 1005-1009 ◽  
Author(s):  
D. J. Fernbach
Keyword(s):  

Sign in / Sign up

Export Citation Format

Share Document